Lead Sponsor

Emory University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Pathologic proven diagnosis of solid tumor malignancy.
•Age ≥ 18.
•KPS ≥ 70.
•Mini Mental Status Exam (MMSE) ≥ 18 prior to study entry.
•RPA class I (KPS ≥ 70, primary cancer controlled, age \< 65, metastases in brain only) or class II (lack of one or more of class I criteria).
•One to ten brain metastatic lesions.

•Previous whole brain radiation therapy.
•Previous radiosurgery to any currently progressive gross metastatic disease.
•Previous radiosurgery to any intracranial site within the prior 6 weeks.
•Recursive partitioning analysis (RPA) class III (KPS \< 70).
•Radiosensitive (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologies.
•Concurrent chemotherapy (no chemotherapy starting 14 days before start of radiation).
•Evidence of leptomeningeal disease by MRI and/or cerebrospinal fluid (CSF) cytology.
•Current pregnancy.
•No metastases to brain stem, midbrain, pons, or medulla or within 7 mm of the optic apparatus (optic nerves and chiasm).

Related studies

NCT07174336 · Breast Neoplasms, Neoplasm Metastasis

NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, and more

NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, and more

NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, and more

NCT06912087 · Head and Neck Neoplasms, Carcinoma, Squamous Cell, and more

Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc